Nephrogen
Curative gene therapies for kidney diseases
Gene Therapy
CRISPR
Biotech
About
Nephrogen is a biotech company developing curative gene therapies for kidney and pancreatic diseases. Kidney disease affects 1 in 7 Americans (~50 million people), has no cure, and accounts for nearly 10% of the Medicare budget.
Build your own investing agent
GPAgent keeps YC listings public and neutral. Fund-specific scoring, notes, and workflow state live in each customer workspace.
Join the GPAgent waitlistDetails
Status
Active
Stage
Early
Team Size
1
Regions
United States of America, America / Canada